Pharmacology Cardiovascular drugs Part I

Slides:



Advertisements
Similar presentations
© 2004 by Thomson Delmar Learning, a part of the Thomson Corporation. Fundamentals of Pharmacology for Veterinary Technicians Chapter 8 Cardiovascular.
Advertisements

Agents used in therapy of Congestive Heart Failure
Antiarrhythmic Agents: Cardiac Stimulants and Depressants
Pharmacology I Drugs Used to Treat Arrhythmias. Arrhythmias Needing Treatment: Atrial Fibrillation/Flutter (AF) Supraventricular Tachycardia (SVT) Ventricular.
Pharmacology DOR 101 Abdelkader Ashour, Ph.D. 9 th Lecture.
1 Cardiac Pathophysiology Part B. 2 Heart Failure The heart as a pump is insufficient to meet the metabolic requirements of tissues. Can be due to: –
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 45 Calcium Channel Blockers.
Calcium Channel Blocking Drugs.
CARDIVASCULAR DRUGS Sanjukta (2009). CARDIOVASCULAR DISEASE AND DRUGS ► Basic cardiovascular physiology and pathology depends on the control of heart.
Cardiac drugs Cardiac glycoside Cardiac glycosides are the most effective drugs for treatment of C.H.F. Digitoxins are plant alkaloids. They increase myocardial.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 18 Adrenergic Antagonists.
Drugs for CCF Heart failure is the progressive inability of the heart to supply adequate blood flow to vital organs. It is classically accompanied by significant.
CONCEPTS OF NORMAL HEMODYNAMICS AND SHOCK
PHARMAKOLOGY VASOPRESSOR DRUGS DJUDJUK RAHMAD BASUKI Lab.Anestesi dan Terapi Intensive RSSA Malang.
Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 22 Heart Failure Drugs.
Chapter 17 Cardiac Stimulants and Depressants. Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved
Cardiac/Vascular Circulation Brenda Rowe, RN, MN, JD Georgia Baptist College of Nursing of Mercer University.
Drug Therapy Heart Failure by Pat Woodbery, MSN, ARNP.
OBJECTIVES At the end of lectures the students should Describe the different classes of drugs used for treatment of acute & chronic heart failure.
Drugs for Congestive Heart Failure
1 Drug Treatment of heart failure. Prof. Azza El-Medani Prof. Abdulrahman Almotrefi.
1 Drug Therapy of heart failure. Prof. Azza El-Medani Prof. Abdulrahman Almotrefi.
PROF. AZZA El-Medany Department of Pharmacology OBJECTIVES At the end of lectures the students should Describe the different classes of drugs used for.
Drugs for Heart Failure Identify the major risk factors that accelerate the progression to heart failure. 2.Relate how the classic symptoms associated.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 21 Positive Inotropic Drugs.
Nursing and heart failure
Bipyridines :(Amrinone,Milrinone ) only available in parenteral form. Half-life 3-6hrs. Excreted in urine.
PICU Resident Talk Stanford School of Medicine Pediatric Critical Care Medicine June 2014.
Chapter 33 Agents Affecting the Autonomic Nervous System.
6/3/ CARDIOVASCULAR MEDICATIONS. FIRST DO NO HARM 6/3/ There are 5 rights to patient medication administration: 1. Right patient 2. Right.
Cardiogenic Shock Dr. Belal Hijji, RN, PhD October 12 & 15, 2011.
Prof. Azza Hafiz El-Medany Prof. Abdulrahman Al-Motrefi.
Systolic Versus Diastolic Failure. Forms of Heart Failure Sytolic Failure Inability of the ventricle to contract normally and expel sufficient blood Inadequate.
23 Antiarrhythmic Drugs.
Diuretics and Antihypertensives
أ. م. د. وحدة اليوزبكي Head of Department of Pharmacology- College of Medicine- University of Mosul-2014 Management of Heart Failure 2.
Drugs used for Congestive Heart Failure
Cardiac Stimulants and Depressants
Question 1 Which of the following is NOT true of the parasympathetic control of the heart? A. It affects muscarinic receptors. B. It decreases heart.
1 Copyright © 2012, 2009, 2006, 2003 by Saunders, an imprint of Elsevier Inc. Chapter 42 CARDIAC GLYCOSIDES, ANTIANGINALS, AND ANTIDYSRHYTHMICS.
Heart Failure  Dfinition:  Clinical features  Underlying causes of HF include Arteriosclerotic heart disease, MI, hypertensive heart disease, valvular.
Drug acting on the Heart Heart failure. Lecture objectives At the end of the this lecture, the student will able to: Describe basic anatomy of the heart.
Adrenergic Antagonists
1 Topics to be addressed: Blood Anatomy of Blood Vessels Anatomy of the Heart The Conduction System The Cardiac Cycle Cardiodynamics Blood Flow and its.
Result from any structural or functional cardiac disorder that impairs the ability of the ventricle to fill with or eject blood to meet the body's metabolic.
CODE BLUE MANAGEMENT DRUG THERAPY
Calcium Channel Blocking Drugs.
Drugs Used to Treat Heart Failure
Drugs used for Congestive Heart Failure
Drugs for Hypertension
Prof. Abdulrahman Al-Motrefi
Drug acting on the Heart
Antidysrhythmic Agents
Drugs Affecting the Cardiovascular System
Treatment of Congestive Heart Failure
Drug Therapy Heart Failure
The Cardiovascular System
Hypertension (High Blood Pressure)
Fluid Balance, Electrolytes, and Acid-Base Disorders
ANTI HYPERTENSIVE DRUGS
Chapter 5 Autonomic Drugs.
Heart Failure Heart cannot pump enough blood to meet the tissue needs of the body, commonly called congestive heart failure Complex clinical syndrome.
2 Cardiovascular Physiology: Function.
Characteristics of Adrenergic Drugs (p. 291)
Antianginal Drugs.
Anti hypertensive Drugs
Drugs Acting on the Heart
CARDIVASCULAR DRUGS.
CARDIOVASCULAR AGENTS
Antiarrhythmic Drugs Types of Cardiac Arrhythmias:
Presentation transcript:

Pharmacology Cardiovascular drugs Part I

1. Which of the following clients is at greatest risk for digital toxicity? A. A 25-year-old client with congenital heart disease B. A 50-year-old client with CHF C. A 60-year-old client after myocardial infarction D. An 80-year-old client with CHF 1. Answer: D. An 80-year-old client with CHF Extremely old clients are at greater risk for digitalis toxicity. Remember when it comes to adversity, the very old and very young are always at highest risk.

2. Which of the following is a contraindication for digoxin administration? A. Blood pressure of 140/90 B. Heart rate above 80 C. Heart rate below 60 D. Respiratory rate above 20 2. Answer: C. Heart rate below 60 The apical heart rate must be monitored during therapy with digoxin, and the drug held for pulse below 60 and above 120. Remember that digoxin lowers the heart rate; therefore, the choice that reflects a low heart rate is the best selection.

3. The action of medication is inotropic when it: A. Decreased afterload B. Increases heart rate C. Increases the force of contraction D. Is used to treat CHF 3. Answer: C. Increases the force of contraction Inotropic drugs increase the force of contraction. Preload, not afterload, is decreased. Chronotropic drugs increase heart rate. Treatment of CHF is an indication for use not an action of inotropic drug.

4. Which is the MOST appropriate action for the nurse to take before administering digoxin? A. Monitor potassium level B. Assess blood pressure C. Evaluate urinary output D. Avoid giving with thiazide diuretic 4. Answer: A. Monitor potassium level Monitoring potassium is especially important because hypokalemia potentiates digoxintoxicity. B and C are incorrect because these data reflect overall CV status but are not specific for digoxin. Choice D are drugs usually administered with digoxin.

5. The therapeutic drug level for digoxin is: A. 0.1-2.0 ng/mg B. 1.0-2.0 ng/mg C. 0.1-0.5 ng/mg D. 0.5-2.0 ng/mg 5. Answer: D. 0.5-2.0 ng/mg This is the correct therapeutic range for digoxin. Every nurse should know this information

6. Blurred vision or halos are signs of: A. Subtherapeutic digoxin levels B. Digoxin toxicity C. Nothing related to digoxin D. Corneal side effects of digoxin 6. Answer: B. Digoxin toxicity Halos is a hallmark sign of digoxin toxicity. A, C and D are incorrect because subtherapeutic digoxin levels have no such effects.

7. Amrinone (Inocor) is used for short term therapy for CHF and acts by which of the following mechanisms? A. Increasing stroke volume and heart rate B. Slowing ventricular rate and increasing cardiac output C. Vasodilating and increasing peripheral vascular resistance D. Increasing cardiac output and enhancing renal perfusion 7. Answer: A. Increasing stroke volume and heart rate The action of amrinone (Inocor) is to increase stroke volume, ejection fraction, and heart rate. Lanoxin, not amrinone, slows ventricular rate and increases cardiac output. The vasodilator effect of amrinone decreases peripheral vascular resistance. Any increase in cardiac output will enhance renal perfusion; this is not just specific to amrinone.

8. Before giving milrinone (Primacor) by an IV infusion to a client with symptoms of CHF, which of the following nursing actions is necessary? A. Record sodium level. B. Administer loading dose over 15 minutes. C. Assess CV status. D. Review medication regimen to identify if client is on IV furosemide (Lasix). 8. Answer: D. Review medication regimen to identify if client is on IV furosemide (Lasix). Milrinone (Primacor) is incompatible with IV furosemide (Lasix), and many clients with CHF are taking furosemide. Assessing potassium, not sodium, is essential. Choice B is not done before administration but during administration. Assessment of CV status is not specific for milrinone and is indicated for any drug that affects the circulatory system.

9. Johanna has ventricular ectopy, which of the following drugs is the first line used to treat her condition? A. quinidine (Cardioquin) B. digoxin (Lanoxin) C. procainamide ( Pronestyl) D. lidocaine (Xylocaine) 9. Answer: D. lidocaine (Xylocaine) Lidocaine is the only choice used to treat ventricular ectopy. A and C are class IA antiarrhythmics. Digoxin is a cardiac glycoside.

10. Class IA antiarrhythmic agents have little effect on: A. AV node B. SA node C. Purkinje fibers D. Bundle of His 10. Answer: B. SA node Class IA antiarrhythmics have little effect on the SA node.

11. Which of the following drugs can cause severe hematologic disorders? A. digoxin (Lanoxin) B. quinidine (Cardioquin) C. disopyramide (Norpace) D. procainamide (Pronestyl 11. Answer: D. procainamide (Pronestyl) Pronestyl is known for this serious side effect. Associate Pronestyl with plasma — P and P. This drug is known for its hematologic side effects.

12. Which of the following ECG findings alerts the nurse that the client needs an antiarrhythmic? A. Normal sinus rhythm B. Sinus bradycardia C. Sinus arrhythmia D. Frequent ventricular ectopy 12. Answer: D. Frequent ventricular ectopy Ventricular ectopy can be a life-threatening arrhythmia; therefore, the client needs an arrhythmic. Other choices are not arrhythmias that need to be treated.

13. When administering an antiarrhythmic agent, which of the following assessment parameters is the most important for the nurse to evaluate? A. ECG B. Pulse rate C. Respiratory rate D. Blood pressure 13. Answer: A. ECG The ECG is the most important parameter to assess. B, C, and D need to be monitored, but the ECG is the most important.

14. Which of the following blood tests will tell the nurse that an adequate amount of drug is present in the blood to prevent arrhythmias? A. Serum chemistries B. Complete blood counts C. Drug levels D. None of the above 14. Answer: C. Drug levels Knowing drug levels (peak and trough) is the only way to ensure there is enough drug in the body to work. Other choices do not demonstrate drug effect.

15. Which of the following drugs should be used only in situations in which the client can be very closely monitored, such as a critical care unit? A. bretylium (Bretylol) B. digoxin (Lanoxin) C. quinidine (Cardioquin) D. inderal (Propranolol) 15. Answer: A. bretylium (Bretylol) Among the choices, this is the only agent that must be monitored this closely. B, C, and D are given to outpatients as oral preparations.

16. The most toxic antiarrhythmic agent is: A. digoxin (Lanoxin) B. lidocaine (Xylocaine) C. amiodarone (Cordarone) D. quinidine (Cardioquin) 16. Answer: C. amiodarone (Cordarone) This is the most toxic drug and should be used only if other less toxic agents have been tried. Digoxin, on the other hand, is cardiotonic, not antiarrhythmic agent. B and D are not known for their toxicity.

17. Epinephrine is used to treat cardiac arrest and status asthmaticus because of which of the following actions? A. Increased speed of conduction and gluconeogenesis B. Bronchodilation and increased heart rate, contractility, and conduction C. Increased vasodilation and enhanced myocardial contractility D. Bronchoconstriction and increased heart rate 17. Answer: B. Bronchodilation and increased heart rate, contractility, and conduction Bronchodilation results from stimulated beta receptors, and cardiac effects result from the stimulation of ß1 receptors. Choice A does not address respiratory effects of medication. Choice C is incorrect because α-stimulating drugs cause vasoconstriction. Bronchodilation, not bronchoconstriction, results from ß2 activity.

18. Following norepinephrine (Levophed) administration, it is essential to the nurse to assess: A. electrolyte status B. color and temperature of toes and fingers C. capillary refill D. ventricular arrhythmias 18. Answer: B. color and temperature of toes and fingers Because decreased perfusion is a side effect of norepinephrine (Levophed), the nurse must check circulation frequently. Capillary refill is not a reliable indication of perfusion in a shock state. Choices A and D are not specific for norepinephrine.

19. Norepinephrine (Levophed) is contraindicated in which of the following conditions? A. Hypovolemic shock B. Neurogenic shock C. Blood pressures above 80-100 mmHg (systolic) D. Decreased renal perfusion 19. Answer: A. Hypovolemic shock Norepinephrine (Levophed) is contraindicated in hypovolemia. Neurogenic shock is an indication for norepinephrine use. Norepinephrine is given to maintain a systolic blood pressure of 80-100 mmHG. Decreased renal perfusion is an adverse reaction.

20. When administering dopamine (Intropin), it is most important for the nurse to know that: A. the drug’s action varies according to the dose. B. the drug may be used instead of fluid replacement. C. the drug cannot be directly mixed in solutions containing bicarbonate or aminophylline. D. the lowest dose to produce the desired effect should be used. 20. Answer: C. the drug cannot be directly mixed in solutions containing bicarbonate or aminophylline. The nurse is responsible for knowing compatible solutions before administering dopamine (Intropin). It is important to know that drug action varies by dose, but the physician is responsible for determining the dose. Dopamine should not be used instead of fluid replacement. Choice D is incorrect because, although it is true, it is not the nurse’s primary concern. It is a collaborative action in which the physician is involved in determining the rate.

21. Dobutamine (Dobutrex) improves cardiac output and is indicated for use in all of the following conditions except: A. septic shock B. congestive heart failure C. arrhythmias D. pulmonary congestion 21. Answer: C. arrhythmias Dobutamine (Dobutrex) is not used to treat arrhythmias. Choices A, B, and D are conditions are conditions that respond to dobutamine.

22. Conduction defects will most likely be an adverse associated with the use of: A. verapamil B. nifedipine C. diltiazem D. felodipine 22. Answer: A. verapamil Verapamil (Calan) has the strongest chronotropic effect and will cause a delay in conduction at the SA and AV nodes.

23. Which of the following calcium channel blockers has the most potent peripheral smooth muscle dilator effect? A. diltiazem B. nifedipine C. nimodipine D. verapamil 23. Answer: B. nifedipine Nifedipine has the strongest peripheral smooth muscle dilator effect of all the calcium channel blockers. Other choices have less of a vasodilator effect.

24. Which of the following adverse reactions is found more often in volume-depleted elderly clients? A. Bradycardia B. Conduction defects C. Ankle edema D. Hypotension 24. Answer: D. Hypotension Hypotension is more likely to occur in the elderly. Choices A, B, and C may occur but are not necessarily increased in frequency in elderly clients.

25. Which of the following calcium channel blockers is used to counteract or prevent cerebral vasospasm? A. verapamil B. nimodipine C. nifedipine D. felodipine 25. Answer: B. nimodipine Nimodipine is given in the neurologic client to prevent cerebral vasospasm. Choices A, C, and D are given in cardiac disease and in the management of hypertension only.

26. Which of the following effects of calcium channel blockers causes a reduction in blood pressure? A. Increased cardiac output B. Decreased peripheral vascular resistance C. Decreased renal blood flow D. Calcium influx into cardiac muscles 26. Answer: B. Decreased peripheral vascular resistance One of the effects of calcium channel blockers is to decrease peripheral vascular resistance. A, C, and D describe the opposite effects of calcium channel blockers.

27. Jason James is taking ß blockers, all of the following should be included in his assessment except: A. Pulmonary function tests B. Baseline ECG C. Glucose level D. Blood pressure 27. Answer: A. Pulmonary function tests Unless the client has a history of pulmonary disease and pulmonary function tests are indicated, there is no need to include this in the routine assessment of the client taking ß blockers.

28. Routine laboratory monitoring in clients taking ß blockers should include: A. Sodium B. Glucose C. Thyrotropin D. Creatine phosphokinase 28. Answer: B. Glucose ß blockers influence glucose metabolism. Although A, C, and D are nice to have, there is no indication that routine assessment of thyrotropin, sodium, or creatine phosphokinase is needed.

29. Competitive antagonism of which of the following occurs at ß receptor sites? A. Catecholamines B. Adrenergic sites C. Acetylcholine D. Norepinephrine 29. Answer: A. Catecholamines Catecholamine receptor sites are blocked by the action of ß-blocking agents. Adrenergic sites may be blocked, but the more appropriate response is catecholamine receptors. Acetylcholine is not affected by ß blockers. Norepinephrine is a catecholamine.

30. ß blockers should be avoided in which of the following conditions? A. Bronchoconstriction B. Hypertension C. Angina D. Myocardial infarction 30. Answer: A. Bronchoconstriction ß blockers should be avoided in bronchoconstrictive disease. B, C, and D are indications for the use of ß blockers.

16. A client

16. A client

16. A client